LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

Начало・Списък с акции・MacroGenics Inc

MacroGenics Inc

Отворен

Сектор Здравеопазване

3.7 -4.39

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.6

Максимум

3.87

Ключови измерители
By Trading Economics
Приходи	-3.5M -56M
Продажби	49M 58M
P/E Средно за сектора	38.83 104.138
EPS	-0.89
Марж на печалбата	-96.273
Служители	339
EBITDA	-4.6M -54M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+84.5 upside

Дивиденти
By Dow Jones
Следващи печалби	5.11.2024 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	3.8M 233M
Предишно отваряне	8.09
Предишно затваряне	3.7

Настроения в новините

By Acuity

73%

27%

345 / 390 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

3.34 / 3.9 Подкрепа & съпротива

MacroGenics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.11.2024 г., 23:05 ч. UTC

Топ новини

Fitch Affirms Australia's Sovereign AAA Rating, But Warns Of Mounting Budget Risks

3.11.2024 г., 21:12 ч. UTC

Печалби

Westpac Says Annual Profit Falls 3%, Upbeat on Prospects -- Update

3.11.2024 г., 20:59 ч. UTC

Печалби

Westpac Says Annual Profit Falls 3%, Upbeat on Prospects

3.11.2024 г., 23:34 ч. UTC

Топ новини

Stocks Poised for Lower Open -- Barrons.com

3.11.2024 г., 23:16 ч. UTC

Топ новини

Печалби

Berkshire Hathway Earnings Weren't as Bad as They Looked -- Barrons.com

3.11.2024 г., 22:50 ч. UTC

Придобивния, сливания и поглъщания

Santos Says Working Interest in PNG LNG Now 39.9%

3.11.2024 г., 22:50 ч. UTC

Придобивния, сливания и поглъщания

Santos Says Kumul to Assume $90 Million of Project Finance Debt Associated With Stake

3.11.2024 г., 22:49 ч. UTC

Придобивния, сливания и поглъщания

Santos Says Final Payment Takes Total Cash Consideration to $602 Million

3.11.2024 г., 22:49 ч. UTC

Придобивния, сливания и поглъщания

Santos Receives Final $241 Million Payment From Kumul

3.11.2024 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

Santos Completes Sale of 2.6% Interest in PNG LNG to Kumul Petroleum

3.11.2024 г., 20:37 ч. UTC

Печалби

Westpac FY 2024 Deposits Increased 5% to A$674 Billion

3.11.2024 г., 20:37 ч. UTC

Печалби

Westpac FY 2024 Loans Increased 4% to A$807 Billion

3.11.2024 г., 20:37 ч. UTC

Печалби

Westpac FY 2024 Impairment Charges 7 Bps of Loans

3.11.2024 г., 20:37 ч. UTC

Печалби

Westpac FY 2024 Operating Expenses A$10.94 Billion, Up 7% Excluding Notable Items

3.11.2024 г., 20:36 ч. UTC

Печалби

Westpac FY 2024 Non-Interest Income A$2.84 Billion, Down 15%

3.11.2024 г., 20:35 ч. UTC

Печалби

Westpac FY 2024 CET1 Level 2 Capital Ratio 12.5%, Up 11 Bps

3.11.2024 г., 20:35 ч. UTC

Печалби

Westpac Raises Share Buyback Program by A$1 Billion

3.11.2024 г., 20:35 ч. UTC

Печалби

Westpac Final Dividend A$0.76/Share

3.11.2024 г., 20:33 ч. UTC

Печалби

Westpac FY 2024 Net Interest Margin Down 1 Bps at 1.95%

3.11.2024 г., 20:32 ч. UTC

Печалби

Westpac FY 2024 Revenue A$21.59 Billion, Flat on FY 2023

3.11.2024 г., 20:32 ч. UTC

Печалби

Westpac FY Net Profit A$6.99 Billion, Down 3%

3.11.2024 г., 18:09 ч. UTC

Топ новини

Boeing Had a Big Week. This One Is Even Bigger. -- Barrons.com

3.11.2024 г., 10:30 ч. UTC

Топ новини

Fed Prepares Rate Cut Amid Economic Contradictions -- WSJ

3.11.2024 г., 03:00 ч. UTC

Топ новини

Disgraced Lebanese Central Banker Who Was a Fugitive Now Awaits His Fate -- WSJ

2.11.2024 г., 13:53 ч. UTC

Топ новини

Печалби

Придобивния, сливания и поглъщания

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- Update

2.11.2024 г., 13:44 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2.11.2024 г., 13:00 ч. UTC

Топ новини

China's EV Makers Set Sights on Latin America in Global Expansion -- WSJ

2.11.2024 г., 12:58 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2.11.2024 г., 12:48 ч. UTC

Топ новини

Печалби

Придобивния, сливания и поглъщания

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- WSJ

2.11.2024 г., 12:32 ч. UTC

Печалби

Berkshire Profits Fell 6% in Third Quarter. The Buybacks Are on Pause. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

MacroGenics Inc Прогноза

Ценова цел

By TipRanks

84.5% нагоре

12-месечна прогноза

Среден 7.14 USD 84.5%

Висок 14 USD

Нисък 4 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за MacroGenics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на MacroGenics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

3.34 / 3.9Подкрепа & съпротива

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bearish.

Настроение

By Acuity

345 / 390 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно MacroGenics Inc

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.